The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Abstract
Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Imatinib (Glivec, formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl tyrosine kinase. A total of 260 patients with CML were enrolled in a phase II trial, of whom 229 had a confirmed diagnosis of CML in blast crisis. Patients were treated with imatinib in daily oral doses of 400 mg or 600 mg. Imatinib induced hematologic responses in 52% of patients and sustained hematologic responses lasting at least 4 weeks in 31% of patients, including complete hematologic responses in 8%. For patients with a sustained response, the estimated median response duration was 10 months. Imatinib induced major cytogenetic responses in 16% of patients, with 7% of the responses being complete. Median survival time was 6.9 months. Nonhematologic adverse reactions were frequent but generally mild or moderate. Episodes of severe cytopenia were also frequent and were attributable to the underlying condition and treatment with imatinib. Drug-related adverse events led to discontinuation of therapy in 5% of patients, most often because of cytopenia, skin disorders, or gastrointestinal reactions. These results demonstrate that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis. Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 3×
“Median age, y (range) 56 (19-81) 57 (19-81) 52 (20-73) 56 (19-81)”
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Hematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationTalpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Acute leukaemia in bcr/abl transgenic mice
Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K., & Groffen, J. (1990) · Nature · doi:10.1038/344251a0 · Cited by 672
Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Kelliher, M. A., McLaughlin, J., Witte, O. N., & Rosenberg, N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6649 · Cited by 514
le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., & Gambacorti-Passerini, C. (2000) · Blood · doi:10.1182/blood.v95.5.1758.005a41_1758_1766 · Cited by 484
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
Deininger, M. W. N., Goldman, J. M., Lydon, N., & Melo, J. V. (1997) · Blood · doi:10.1182/blood.v90.9.3691 · Cited by 482
Chronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Weisberg, E., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.11.3498 · Cited by 401
In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor
le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., & Gambacorti-Passerini, C. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.2.163 · Cited by 374
Elefanty, A. G., Hariharan, I. K., & Cory, S. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08212.x · Cited by 344
Gambacorti-Passerini, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1641 · Cited by 320
Gambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., et al. (1997) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.1997.0155 · Cited by 316
Roots of Clinical Resistance to STI-571 Cancer Therapy
Barthe, C., Cony-Makhoul, P., Melo, J. V., & Mahon, J. R. F.-X. (2001) · Science · doi:10.1126/science.293.5538.2163a · Cited by 271
Characteristics of accelerated disease in chronic myelogenous leukemia
Kantarjian, H. M., Dixon, D., Keating, M. J., Talpaz, M., Walters, R. S., McCredie, K. B., & Freireich, E. J. (1988) · Cancer · doi:10.1002/1097-0142(19880401)61:7<1441::aid-cncr2820610727>3.0.co;2-c · Cited by 270
Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y., & Furukawa, Y. (2001) · Blood · doi:10.1182/blood.v97.7.1999 · Cited by 262
ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA
Speck, B., Bortin, M., Champlin, R., Goldman, J., Herzig, R., Mcglave, P., Messner, H., Weiner, R., & Rimm, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92179-2 · Cited by 259
Staging and prognosis in chronic myelogenous leukemia.
Sokal, J. E., Baccarani, M., Russo, D., & Tura, S. (1988) · PubMed · Cited by 210
Weisdorf, D. J., Anasetti, C., Antin, J. H., Kernan, N. A., Kollman, C., Snyder, D., Petersdorf, E., Nelson, G., & McGlave, P. (2002) · Blood · doi:10.1182/blood.v99.6.1971 · Cited by 196
Sacchi, S., Kantarjian, H. M., O'Brien, S., Cortes, J., Rios, M. B., Giles, F. J., Beran, M., Koller, C. A., Keating, M. J., & Talpaz, M. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991215)86:12<2632::aid-cncr7>3.0.co;2-a · Cited by 184
Topaly, J., Zeller, W., & Fruehauf, S. (2001) · Leukemia · doi:10.1038/sj.leu.2402041 · Cited by 170
Characteristics of the Terminal Phase of Chronic Granulocytic Leukemia
Karanas, A., & Silver, R. T. (1968) · Blood · doi:10.1182/blood.v32.3.445.445 · Cited by 141
Gratwohl, A. A., Hermans, J., Niederwieser, D. W., Frassoni, F., Arcese, W., Gahrton, G., Bandini, G., Carreras, E., Vernant, J., & Bosi, A. (1993) · PubMed · Cited by 140
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
Kantarjian, H., O'Brien, S., Keating, M. J., Beran, M., Estey, E. H., Giralt, S. A., Kornblau, S. M., Rios, M., Vos, D. D., & Talpaz, M. (1997) · Leukemia · doi:10.1038/sj.leu.2400796 · Cited by 130
Derderian, P. M., Kantarjian, H. M., Talpaz, M., O'Brien, S. M., Cork, A., Estey, E. H., Pierce, S. A., & Keating, M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90122-6 · Cited by 109
Kantarjian, H. M., Talpaz, M., Kontoyiannis, D. P., Gutterman, J., Keating, M., Estey, E. H., O'Brien, S., Rios, M. B., Beran, M., & Deisseroth, A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.3.398 · Cited by 65
A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia
Dutcher, J. P., Coletti, D., Paietta, E. M., & Wiernik, P. H. (1997) · Leukemia Research · doi:10.1016/s0145-2126(96)00108-7 · Cited by 49
OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA
Spencer, A. G., O’Brien, S. G., & Goldman, J. M. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05236.x · Cited by 29
Cited by
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Self-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., Bekele, B. N., Raber-Durlacher, J., Donnelly, J. P., Rubenstein, E. B., et al. (2004) · Cancer · doi:10.1002/cncr.20162 · Cited by 1,417
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Metadata
- Authors
- Sawyers, C. L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-05-15
- Volume
- 99
- Issue
- 10
- Pages
- 3530-3539
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2142969636
- Cited by
- 1,146
- References
- 38
- FWCI
- 51.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.